Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the company’s clinical candidate for the treatment of hypoparathyroidism.
